CA2709314A1 - 5-alkyl/alcenyl-3-cyanopyridines en tant qu'inhibiteurs de kinase - Google Patents

5-alkyl/alcenyl-3-cyanopyridines en tant qu'inhibiteurs de kinase Download PDF

Info

Publication number
CA2709314A1
CA2709314A1 CA2709314A CA2709314A CA2709314A1 CA 2709314 A1 CA2709314 A1 CA 2709314A1 CA 2709314 A CA2709314 A CA 2709314A CA 2709314 A CA2709314 A CA 2709314A CA 2709314 A1 CA2709314 A1 CA 2709314A1
Authority
CA
Canada
Prior art keywords
methyl
amino
indol
nicotinonitrile
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2709314A
Other languages
English (en)
Inventor
Lawrence Nathan Tumey
Diane Harris Boschelli
Niala Bhagirath
Joan Jowen Chen
Middleton Brawner Floyd, Jr.
Zhong Li
Chuansheng Niu
Jaechul Shim
Yan Wang
Yanong Daniel Wang
Biqi Wu
Clark N. Eid, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2709314A1 publication Critical patent/CA2709314A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2709314A 2007-12-13 2008-12-12 5-alkyl/alcenyl-3-cyanopyridines en tant qu'inhibiteurs de kinase Abandoned CA2709314A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1345707P 2007-12-13 2007-12-13
US61/013,457 2007-12-13
PCT/US2008/086594 WO2009076602A1 (fr) 2007-12-13 2008-12-12 5-alkyl/alcényl-3-cyanopyridines en tant qu'inhibiteurs de kinase

Publications (1)

Publication Number Publication Date
CA2709314A1 true CA2709314A1 (fr) 2009-06-18

Family

ID=40429261

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2709314A Abandoned CA2709314A1 (fr) 2007-12-13 2008-12-12 5-alkyl/alcenyl-3-cyanopyridines en tant qu'inhibiteurs de kinase

Country Status (5)

Country Link
EP (1) EP2229377A1 (fr)
JP (1) JP2011506475A (fr)
CA (1) CA2709314A1 (fr)
CL (1) CL2008003675A1 (fr)
WO (1) WO2009076602A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101452579B1 (ko) * 2012-08-17 2014-10-21 주식회사 두산 신규 화합물 및 이를 포함하는 유기 전계 발광 소자
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
EP3275442B1 (fr) 2015-03-25 2021-07-28 National Cancer Center Agent thérapeutique contre le cancer du canal cholédoque
WO2017013593A1 (fr) 2015-07-22 2017-01-26 Lupin Limited Dérivés d'isoquinolinone utilisés en tant qu'inhibiteurs de parp
CN108367000A (zh) 2015-12-17 2018-08-03 卫材R&D管理有限公司 用于乳腺癌的治疗剂
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
WO2024151919A1 (fr) * 2023-01-13 2024-07-18 Ifm Due, Inc. Composés et compositions pour traiter des états pathologiques associés à une activité de sting

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781591B2 (en) * 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
EP1888529A2 (fr) * 2005-05-18 2008-02-20 Wyeth Inhibiteurs 3-cyanoquinoline de la tpl2 kinase et procedes de production et d'utilisation associes

Also Published As

Publication number Publication date
WO2009076602A8 (fr) 2010-02-18
EP2229377A1 (fr) 2010-09-22
CL2008003675A1 (es) 2009-03-20
JP2011506475A (ja) 2011-03-03
WO2009076602A1 (fr) 2009-06-18

Similar Documents

Publication Publication Date Title
ES2543151T3 (es) Derivados de 2-piridina como moduladores del receptor Smoothened
JP5969054B2 (ja) Smacミメチックスとしての6−アルキニルピリジン
KR20170117479A (ko) 치환된 모노- 및 폴리아자나프탈렌 유도체 및 이의 용도
CA2709314A1 (fr) 5-alkyl/alcenyl-3-cyanopyridines en tant qu'inhibiteurs de kinase
AU2006297948A1 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
TW200306180A (en) New compounds
WO2010080474A1 (fr) Carbazole et inhibiteurs de la carboline kinase
KR20130116287A (ko) 3-(아미노아릴)-피리딘 화합물
JP2010514822A (ja) 新規なフェニル(4−フェニルピリミジン−2−イル)アミン誘導体、薬物としてのこれらの調製、医薬組成物および基本的にikk阻害剤としてのこれらの使用
JP2009501711A (ja) 新規2,4−ジアニリノピリミジン誘導体、その調製、医薬、医薬組成物としての、特に、ikk阻害剤としてのそれらの使用
KR20110118611A (ko) 암의 치료를 위한 wnt 신호전달 경로 억제제로서의 피리딘계 및 피리미딘계 화합물
CA2610446A1 (fr) Compose heterocyclique azote
CA2682340A1 (fr) [2,6]naphthyridines utiles en tant qu'inhibiteurs des proteines kinases
JP2008542433A (ja) CDK−1インヒビターとしてのα−カルボリン
WO2013100672A1 (fr) Dérivé d'indazole 3,6-disubstitué ayant une activité d'inhibition de protéine kinase
CN115515589A (zh) Ulk1/2抑制剂及其使用方法
EP1657241A1 (fr) Nouveaux urées d' anthranylamide pyridine ayant une activité inhibitrice de kinase du récepteur de VEGF
WO2011019060A1 (fr) Inhibiteur de signal hedgehog
AU2021410926A1 (en) Tetrahydrothienopyrimidinesulfonamide compounds
CN113461670B (zh) 作为转染期间重排激酶抑制剂的新的化合物
WO2014160177A2 (fr) Inhibiteurs quinazolines de pi3k
US12258328B2 (en) 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors
WO2025163050A1 (fr) Nouveaux derives amides, compositions pharmaceutiques les contenant et leurs utilisations comme inhibiteurs de sos1
EP2229376A1 (fr) 3-cyanopyridines indole-substituées en tant qu'inhibiteurs de kinase
HK40066516A (zh) 作为治疗剂的4- (咪唑并[1,2-a]吡啶-3-基)-n-(吡啶基)嘧啶-2-胺的衍生物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20121212